● Recruiting

Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

Condition: Ischemic Stroke · Sponsor: Tianjin Institute of Pharmaceutical Research Co., Ltd

PhasePhase 2

Planned participants600

Who can joinAll sexes, 40 Years to no upper limit

Healthy volunteersNo

About this study

This study is designed to evaluate efficacy and safety of tiprogrel in the treatment of patients with acute ischemic cerebrovascular events.

This description comes directly from the study's public registry record.

Talk to the study team

Xiaofei Pan · +86-22-23006825 · panxiaofei@tipr.com.cn

Always discuss trial participation with your own doctor first.

Locations (2)

Central Hospital Affiliated to Shenyang Medical College	Shenyang, Liaoning, China	Recruiting
Beijing Tiantan Hosptial, Capital Medical University	Beijing, China	Not Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06601127